Toll Free: 1-888-928-9744
Published: Nov, 2014 | Pages:
38 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Eddingpharm - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Eddingpharm - Product Pipeline Review - 2014', provides an overview of the Eddingpharm's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Eddingpharm's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Eddingpharm including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Eddingpharm's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Eddingpharm's pipeline products Reasons to buy - Evaluate Eddingpharm's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Eddingpharm in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Eddingpharm's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Eddingpharm and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Eddingpharm - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Eddingpharm and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Eddingpharm Snapshot 5 Eddingpharm Overview 5 Key Information 5 Key Facts 5 Eddingpharm - Research and Development Overview 6 Key Therapeutic Areas 6 Eddingpharm - Pipeline Review 8 Pipeline Products by Stage of Development 8 Pipeline Products - Monotherapy 9 Pipeline Products - Partnered Products 10 Partnered Products/Combination Treatment Modalities 11 Eddingpharm - Pipeline Products Glance 12 Eddingpharm - Clinical Stage Pipeline Products 12 Phase II Products/Combination Treatment Modalities 12 Phase I Products/Combination Treatment Modalities 13 Eddingpharm - Early Stage Pipeline Products 14 Preclinical Products/Combination Treatment Modalities 14 Eddingpharm - Unknown Stage Pipeline Products 15 Unknown Products/Combination Treatment Modalities 15 Eddingpharm - Drug Profiles 16 IMP-321 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 telatinib 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 ALX-0141 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 EDP-317 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 ACTB-1010 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 ACTB-1011 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 ozoralizumab 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 Eddingpharm - Pipeline Analysis 26 Eddingpharm - Pipeline Products by Target 26 Eddingpharm - Pipeline Products by Route of Administration 28 Eddingpharm - Pipeline Products by Molecule Type 29 Eddingpharm - Pipeline Products by Mechanism of Action 30 Eddingpharm - Recent Pipeline Updates 32 Eddingpharm - Locations And Subsidiaries 36 Head Office 36 Other Locations & Subsidiaries 36 Appendix 37 Methodology 37 Coverage 37 Secondary Research 37 Primary Research 37 Expert Panel Validation 37 Contact Us 38 Disclaimer 38
List of Tables Eddingpharm, Key Information 5 Eddingpharm, Key Facts 5 Eddingpharm - Pipeline by Indication, 2014 7 Eddingpharm - Pipeline by Stage of Development, 2014 8 Eddingpharm - Monotherapy Products in Pipeline, 2014 9 Eddingpharm - Partnered Products in Pipeline, 2014 10 Eddingpharm - Partnered Products/ Combination Treatment Modalities, 2014 11 Eddingpharm - Phase II, 2014 12 Eddingpharm - Phase I, 2014 13 Eddingpharm - Preclinical, 2014 14 Eddingpharm - Unknown, 2014 15 Eddingpharm - Pipeline by Target, 2014 27 Eddingpharm - Pipeline by Route of Administration, 2014 28 Eddingpharm - Pipeline by Molecule Type, 2014 29 Eddingpharm - Pipeline Products by Mechanism of Action, 2014 31 Eddingpharm - Recent Pipeline Updates, 2014 32 Eddingpharm, Other Locations 36
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.